Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment January 4, 2023 Read more
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis November 15, 2022 Read more
Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment October 18, 2022 Read more
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment September 15, 2022 Read more
